首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Modified Chaihu Shugan Powder for Functional Dyspepsia: Meta-Analysis for Randomized Controlled Trial
【24h】

Modified Chaihu Shugan Powder for Functional Dyspepsia: Meta-Analysis for Randomized Controlled Trial

机译:功能性消化不良的改性柴胡疏肝散:随机对照试验的荟萃分析

获取原文
           

摘要

Context. Modified Chaihu Shugan powder (MCSP) is a popular traditional Chinese herbal formula for functional dyspepsia, which is revised from Chaihu Shugan San and recorded in a medical classic works of China. However, its role and effect in treating functional dyspepsia have not been well established.Objective. To assess the effect and safety of modified Chaihu Shugan powder for functional dyspepsia.Methods. We searched the published and unpublished studies up to August 2012. Only RCTs of modified Chaihu Shugan powder with or without prokinetic drugs versus prokinetic drugs in the patients diagnosed with functional dyspepsia were included.Results. Twenty-two clinical trials involving 1998 participants were included. There were evidences that modified Chaihu Shugan powder (RR = 1.20, 95%, CI 1.14 to 1.27) and modified Chaihu Shugan powder plus prokinetic drugs (RR = 1.18, 95%, CI 1.11 to 1.25) were significantly better treatment options than prokinetic drugs alone in improving symptoms. No serious adverse events were described in the included trials.Conclusions. This meta-analysis showed that modified Chaihu Shugan powder alone or in combination with prokinetic drugs might be more effective than prokinetic drugs alone. However, with poor methodological quality, all the included trials were at high risk of bias. Further large-scale high-quality trials are required for assessment.
机译:上下文。改性柴胡疏肝散(MCSP)是一种功能性消化不良的流行中草药配方,它是从柴胡疏肝散修订而来,并记录在中国的医学经典著作中。然而,其在治疗功能性消化不良中的作用和效果尚不明确。评估改性柴胡疏肝散对功能性消化不良的疗效和安全性。我们检索了截至2012年8月的已发表和未发表的研究。仅包括经确诊的功能性消化不良患者中,加或不加促运动药物与促运动药物的改良柴胡疏肝散的随机对照试验。结果。纳入了涉及1998年参与者的22项临床试验。有证据表明,改良的柴胡疏肝散(RR = 1.20,95%,CI 1.14至1.27)和改良的柴胡疏肝散加促动力药(RR = 1.18,95%,CI 1.11至1.25)比促动药物明显更好的治疗选择独自改善症状。在纳入的试验中没有描述严重的不良事件。这项荟萃分析表明,单独或与促动力药合用的改性柴胡疏肝散可能比单独的促动力药更有效。但是,由于方法学质量较差,所有纳入的试验都有偏倚的高风险。评估还需要进一步的大规模高质量试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号